Predictors of response, progression‐free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high‐risk neuroblastoma

The New Approaches to Neuroblastoma Therapy Response Criteria (NANTRC) were developed to optimize response assessment in patients with recurrent/refractory neuroblastoma. Response predictors and associations of the NANTRC version 1.0 (NANTRCv1.0) and prognostic factors with outcome were analyzed.

[1]  F. Moreno,et al.  COVD-28. IMPACT OF COVID‐19 IN CHILDHOOD CENTRAL NERVOUS SYSTEM TUMORS IN ARGENTINA. REPORT FROM THE NATIONAL PEDIATRIC CANCER REGISTRY, ROHA NETWORK , 2020, Neuro-Oncology.

[2]  K. McHugh,et al.  Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  F. Berthold,et al.  Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group , 2017, Cancer.

[4]  S. Groshen,et al.  A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High‐Risk Neuroblastoma , 2016, Pediatric blood & cancer.

[5]  F. Moreno,et al.  Childhood Neuroblastoma: Incidence and Survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000–2012 , 2016, Pediatric blood & cancer.

[6]  D. Koh,et al.  Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements , 2016, Pediatric blood & cancer.

[7]  Gudrun Schleiermacher,et al.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Groshen,et al.  131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  S. Groshen,et al.  Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study , 2014, BMC Research Notes.

[10]  S. Groshen,et al.  Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium , 2013, Pediatric blood & cancer.

[11]  A. Naranjo,et al.  Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group , 2013, The Journal of Nuclear Medicine.

[12]  K. Matthay,et al.  131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. , 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[13]  J Jack Lee,et al.  Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Groshen,et al.  Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial , 2012, The Journal of Nuclear Medicine.

[15]  R. Kay.  The Analysis of Survival Data , 2012 .

[16]  S. Groshen,et al.  Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial , 2012, Clinical Cancer Research.

[17]  F. Berthold,et al.  Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Groshen,et al.  A phase I study of zoledronic acid and low‐dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study , 2011, Pediatric blood & cancer.

[19]  S. Groshen,et al.  Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study , 2011, Cancer Chemotherapy and Pharmacology.

[20]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[21]  Lewington,et al.  Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force , 2010, British Journal of Cancer.

[22]  S. Parodi,et al.  Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. , 2009, European journal of cancer.

[23]  S. Groshen,et al.  Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Matthay,et al.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Groshen,et al.  Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. McGregor,et al.  Disease control intervals in high‐risk neuroblastoma , 2008, Cancer.

[27]  S. Groshen,et al.  Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Bernard Asselain,et al.  Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[30]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[31]  N. Cheung,et al.  Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Hallahan,et al.  Patterns of failure following total body irradiation and bone marrow transplantation with or without a radiotherapy boost for advanced neuroblastoma. , 1995, International journal of radiation oncology, biology, physics.

[33]  D. Stram,et al.  Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[35]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. R. Hocking.  The analysis and selection of variables in linear regression , 1976 .

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[38]  S. Wyard,et al.  THE NATURAL DURATION OF CANCER , 1925, Canadian Medical Association journal.

[39]  W. S. Lazarus-Barlow,et al.  THE NATURAL DURATION OF CANCER , 1924, British medical journal.

[40]  S. Groshen,et al.  Cancer Therapy : Clinical Phase I Study of Vincristine , Irinotecan , and 131 I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma : A New Approaches to Neuroblastoma Therapy Trial , 2012 .

[41]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[42]  L. Ries,et al.  Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .

[43]  B. Bostrom,et al.  The value of bone marrow trephine biopsy in the diagnosis of metastatic neuroblastoma. , 1985, The American journal of pediatric hematology/oncology.